Patients with NSCLC undergoing neoadjuvant chemotherapy or combination chemoradiotherapy prior to curative-intent surgery demonstrated that 36–57% of patients had either an increase or decrease in PD-L1 expression in their post-treatment specimen compared to the pre-treatment diagnostic biopsy [9–12]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.